View
Semantic Search: Just dropped: Most significant metabolic finding in years
Just dropped: Most significant metabolic finding in years
Score 0.834
· Account tjphuhs@gmail.com
· 4/1/2026, 9:13:13 AM
Just dropped: Most significant metabolic finding in years from hello@drinklmnt.com on 2026-04-01T13:13:13.000Z access to the full draft — so you can review the findings, context, and early interpretations for yourself. [Read Summary](https://science.drinklmnt.com/did-you-know/preliminary-findings-pinkle-monade-doing-a-lot?utm_source=klaviyo&utm_medium=email&utm_campaign=weekly-newsletter&utm_term=just-dropped-most-significant-metabolic-finding-in-years&utm_content=blog) https://science.drinklmnt
Just dropped: Most significant metabolic finding in years
Score 0.813
· Account tjphuhs@gmail.com
· 4/1/2026, 9:13:13 AM
Just dropped: Most significant metabolic finding in years from hello@drinklmnt.com on 2026-04-01T13:13:13.000Z https://drinklmnt.com?utm_source=klaviyo&utm_medium=email&utm_campaign=&utm_term=&utm_content=universal-header-newsletter [MY ACCOUNT](https://drinklmnt.com/account/login?utm_source=klaviyo&utm_medium=email&utm_campaign=&utm_term=&utm_content=universal-header-newsletter) [DRINKLMNT.COM](https://drinklmnt.com?utm_source=klaviyo&utm_medium=email&utm_campaign=&utm_term=&utm_content=univers
Fwd: Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine
Score 0.677
· Account tjphuhs@gmail.com
· 4/24/2026, 9:42:34 AM
Fwd: Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine from tjphuhs@gmail.com on 2026-04-24T13:42:34.000Z ---------- Forwarded message ---------- From: Derek from Research Radar <derekpruski@substack.com> Date: Apr 24, 2026 at 9:10 AM -0400 To: tjphuhs@gmail.com Subject: Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine > Let’s talk about one of the biggest stories currently brewing in the obesity and metabolic disease space — Eli Lilly’s rumored quintup
Fwd: Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine
Score 0.677
· Account oc.tjphuhs@gmail.com
· 4/24/2026, 9:42:34 AM
Fwd: Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine from tjphuhs@gmail.com on 2026-04-24T13:42:34.000Z ---------- Forwarded message ---------- From: Derek from Research Radar <derekpruski@substack.com> Date: Apr 24, 2026 at 9:10 AM -0400 To: tjphuhs@gmail.com Subject: Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine > Let’s talk about one of the biggest stories currently brewing in the obesity and metabolic disease space — Eli Lilly’s rumored quintup
A New MOTS-c Study Just Dropped — Here's What It Actually Means
Score 0.673
· Account tjphuhs@gmail.com
· 4/4/2026, 9:43:08 PM
A New MOTS-c Study Just Dropped — Here's What It Actually Means from derekpruski@substack.com on 2026-04-05T01:43:08.000Z a number of mitochondrial parameters — including redox handling, mitochondrial integrity, and OXPHOS efficiency — jointly indicating a mechanistic basis for the observed functional improvements. Breaking those terms down: Redox handling — how well the cell manages oxidative stress Mitochondrial integrity — the structural health of the mitochondria themselves OXPHOS efficiency
we made a metabolic discovery
Score 0.666
· Account tjphuhs@gmail.com
· 3/22/2026, 11:00:22 PM
we made a metabolic discovery from hello@bryanjohnson.com on 2026-03-23T03:00:22.000Z [Blueprint Homepage](https://blueprint.bryanjohnson.com) Hi friend, This is email 3 in a 3-part series on magic mushrooms. In the last two emails, I shared why we began testing psilocybin as a potential longevity therapy, the scientific rationale behind it, and the fully quantified protocol measuring 249 biomarkers across three medically supervised doses ([read more here](https://blueprint.bryanjohnson.com/blog
A New MOTS-c Study Just Dropped — Here's What It Actually Means
Score 0.663
· Account tjphuhs@gmail.com
· 4/4/2026, 9:43:08 PM
A New MOTS-c Study Just Dropped — Here's What It Actually Means from derekpruski@substack.com on 2026-04-05T01:43:08.000Z View this post on the web at https://derekpruski.substack.com/p/a-new-mots-c-study-just-dropped-heres A new peer-reviewed study on MOTS-c was published January 9th out of the University of Copenhagen, and I’ve seen a little chatter about it online — including Coach Cam touching on it on TikTok. I wanted to give my own read on it for the community, broken down in a way that ac
Non-GLP Fat Loss Compounds Ranked
Score 0.662
· Account tjphuhs@gmail.com
· 5/5/2026, 6:03:45 PM
Non-GLP Fat Loss Compounds Ranked from huntershealthhacks@mail.beehiiv.com on 2026-05-05T22:03:45.000Z 25 to 200 mcg post-workout. Watch your blood sugar. Always have carbs on hand. Hypoglycemia is the real risk. **Cardarine (GW501516).** A PPAR agonist that shifts you toward fatty acid oxidation. By itself, it will not melt fat. Paired with cardio, you get way more out of every session. I run 10 mg per day for 4 to 8 weeks. There is a cancer signal in mice (in both directions), which is why I k
NMN vs NR: A Deep Dive For Researchers Who Didn’t Get What They Hoped From NAD+
Score 0.654
· Account tjphuhs@gmail.com
· 5/11/2026, 10:07:04 AM
NMN vs NR: A Deep Dive For Researchers Who Didn’t Get What They Hoped From NAD+ from derekpruski@substack.com on 2026-05-11T14:07:04.000Z track record of human trials. NMN’s evidence base is catching up fast — as of mid-2025, at least five NMN RCTs and ten NR RCTs have reported metabolic outcomes, with more on the way. What The Human Data Shows This is where the picture sharpens. We’re not just looking at rodents anymore. The head-to-head trial (Christen et al., 2025, Nature Metabolism). The fir
Peptira Just Dropped 3 New Amino Blends — And None of Them Contain B12
Score 0.654
· Account tjphuhs@gmail.com
· 3/30/2026, 4:25:58 PM
Peptira Just Dropped 3 New Amino Blends — And None of Them Contain B12 from derekpruski@substack.com on 2026-03-30T20:25:58.000Z processes NAD+ is a coenzyme required for energy production in every cell in the body. Research interest around NAD+ has expanded significantly in recent years, particularly around its decline with age and the downstream effects on cellular function and longevity B6 and methionine are studied as methylation cofactors — methylation being the process the body uses to reg
Fwd: Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine
Score 0.654
· Account tjphuhs@gmail.com
· 4/24/2026, 9:42:34 AM
Fwd: Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine from tjphuhs@gmail.com on 2026-04-24T13:42:34.000Z > • > News-Medical coverage: “New quintuple agonist shows promise for treating obesity and type 2 diabetes.” September 21, 2025. news-medical.net > • > Andreassen KV, et al. Research on Dual Amylin and Calcitonin Receptor Agonists (DACRAs, KBP-042, KBP-089) — various publications > • > Eli Lilly pipeline page (no quintuple currently listed): lilly.com/science/research-de
Fwd: Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine
Score 0.654
· Account oc.tjphuhs@gmail.com
· 4/24/2026, 9:42:34 AM
Fwd: Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine from tjphuhs@gmail.com on 2026-04-24T13:42:34.000Z > • > News-Medical coverage: “New quintuple agonist shows promise for treating obesity and type 2 diabetes.” September 21, 2025. news-medical.net > • > Andreassen KV, et al. Research on Dual Amylin and Calcitonin Receptor Agonists (DACRAs, KBP-042, KBP-089) — various publications > • > Eli Lilly pipeline page (no quintuple currently listed): lilly.com/science/research-de
SS-31: The Mitochondrial Peptide With Way More Uses Than People Realize
Score 0.651
· Account tjphuhs@gmail.com
· 5/6/2026, 2:59:21 PM
SS-31: The Mitochondrial Peptide With Way More Uses Than People Realize from derekpruski@substack.com on 2026-05-06T18:59:21.000Z brain concentrations achieved with subcutaneous dosing are lower than other tissues. Use this section as a “promising direction” rather than “established outcome.” The Less-Discussed Applications A quick rundown of areas where SS-31 has preclinical research that almost never gets talked about: Hearing loss. SS-31 has been studied for noise-induced and age-related hear
Fwd: Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine
Score 0.651
· Account tjphuhs@gmail.com
· 4/24/2026, 9:42:34 AM
Fwd: Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine from tjphuhs@gmail.com on 2026-04-24T13:42:34.000Z actually does. > GLP-1 (Glucagon-Like Peptide-1) > This is the backbone of every modern weight loss drug, from semaglutide forward. GLP-1 stimulates insulin release when blood sugar is high, suppresses glucagon (preventing unnecessary sugar release from the liver), and slows gastric emptying so you feel full longer. It also acts directly on the brain’s appetite centers i
Fwd: Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine
Score 0.651
· Account oc.tjphuhs@gmail.com
· 4/24/2026, 9:42:34 AM
Fwd: Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine from tjphuhs@gmail.com on 2026-04-24T13:42:34.000Z actually does. > GLP-1 (Glucagon-Like Peptide-1) > This is the backbone of every modern weight loss drug, from semaglutide forward. GLP-1 stimulates insulin release when blood sugar is high, suppresses glucagon (preventing unnecessary sugar release from the liver), and slows gastric emptying so you feel full longer. It also acts directly on the brain’s appetite centers i
A New MOTS-c Study Just Dropped — Here's What It Actually Means
Score 0.650
· Account tjphuhs@gmail.com
· 4/4/2026, 9:43:08 PM
A New MOTS-c Study Just Dropped — Here's What It Actually Means from derekpruski@substack.com on 2026-04-05T01:43:08.000Z pages, has described MOTS-c as promoting biogenesis — meaning it helps you grow more mitochondria. This study says that’s not what’s primarily happening. MOTS-c is making your existing mitochondria work better. Same number, higher output. Think of it like tuning an engine rather than adding more cylinders. How Does It Do That? The Two Pathways The researchers found that MOTS-
Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine
Score 0.648
· Account tjphuhs@gmail.com
· 4/24/2026, 9:05:46 AM
Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine from derekpruski@substack.com on 2026-04-24T13:05:46.000Z still mouse data Mouse-to-market is typically 8-12 years Retatrutide is what’s actually arriving soon Eloralintide is what’s actually advancing through Phase 3 for amylin The quintuple, if real, is a late-decade story The most important thing to do right now is stay curious and stay patient. Let the science play out. Don’t build expectations around compounds that haven
Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine
Score 0.646
· Account tjphuhs@gmail.com
· 4/24/2026, 9:05:46 AM
Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine from derekpruski@substack.com on 2026-04-24T13:05:46.000Z single dose and push efficacy into territory that previously only bariatric surgery could reach. ═══════════════════════════════ THE FIVE RECEPTORS AND WHY EACH MATTERS The rumored Lilly quintuple reportedly targets GLP-1, GIP, glucagon, amylin, and calcitonin. Let’s break down what each one actually does. GLP-1 (Glucagon-Like Peptide-1) This is the backbone of every m
Fwd: MOTS-c vs NAD+: The Beginner's Guide to Understanding Two Mitochondrial Research Compounds
Score 0.646
· Account tjphuhs@gmail.com
· 4/24/2026, 1:28:54 PM
Fwd: MOTS-c vs NAD+: The Beginner's Guide to Understanding Two Mitochondrial Research Compounds from tjphuhs@gmail.com on 2026-04-24T17:28:54.000Z mode. > • > Improves insulin sensitivity in preclinical models, meaning muscle cells pull glucose out of circulation more efficiently. > • > Appears to protect against metabolic stress in rodent studies (high-fat diet models). > • > Levels naturally decline with age, which some researchers think contributes to age-related metabolic dysfunction. > > >
Fwd: MOTS-c vs NAD+: The Beginner's Guide to Understanding Two Mitochondrial Research Compounds
Score 0.646
· Account oc.tjphuhs@gmail.com
· 4/24/2026, 1:28:54 PM
Fwd: MOTS-c vs NAD+: The Beginner's Guide to Understanding Two Mitochondrial Research Compounds from tjphuhs@gmail.com on 2026-04-24T17:28:54.000Z mode. > • > Improves insulin sensitivity in preclinical models, meaning muscle cells pull glucose out of circulation more efficiently. > • > Appears to protect against metabolic stress in rodent studies (high-fat diet models). > • > Levels naturally decline with age, which some researchers think contributes to age-related metabolic dysfunction. > > >
Fwd: When Ozempic stops working (and what 10% of users already know)
Score 0.641
· Account tjphuhs@gmail.com
· 3/17/2026, 2:05:41 PM
Fwd: When Ozempic stops working (and what 10% of users already know) from tjphuhs@gmail.com on 2026-03-17T18:05:41.000Z Rate Problem Retatrutide is Eli Lilly's triple agonist (GIP/GLP-1/glucagon). Early results: up to 24.2% weight loss at 48 weeks per the NEJM Phase 2 trial. But buried in the data: dose-dependent increases in heart rate peaking at 24 weeks. The glucagon receptor component is the likely culprit. At the 12mg dose, heart rate elevations were clinically notable. Users report resting
we made a metabolic discovery
Score 0.640
· Account tjphuhs@gmail.com
· 3/22/2026, 11:00:22 PM
we made a metabolic discovery from hello@bryanjohnson.com on 2026-03-23T03:00:22.000Z cooled, showing cognitive effort and introspection + my arms cooled, showing peripheral vasoconstriction Overall, there was sympathetic activation, peripheral vasoconstriction, and increased cardiovascular load, leading to increased core and reduced peripheral blood flow. Around the peak (2.5 hrs), my heart rate was still elevated by 15 bpm (55 bpm to 70 bpm), and interestingly, my fingertip SpO₂ was decreased
SS-31: The Mitochondrial Peptide With Way More Uses Than People Realize
Score 0.640
· Account tjphuhs@gmail.com
· 5/6/2026, 2:59:21 PM
SS-31: The Mitochondrial Peptide With Way More Uses Than People Realize from derekpruski@substack.com on 2026-05-06T18:59:21.000Z one of the most underrated areas of SS-31 research, and it makes total sense once you understand the kidney’s biology. Why kidneys are mitochondria-dependent. The kidney is one of the most metabolically demanding organs in the body. Specifically, the proximal tubules — the part of the nephron responsible for reabsorbing nutrients, electrolytes, and water back into the
MOTS-c vs NAD+: The Beginner's Guide to Understanding Two Mitochondrial Research Compounds
Score 0.640
· Account tjphuhs@gmail.com
· 4/24/2026, 1:18:04 PM
MOTS-c vs NAD+: The Beginner's Guide to Understanding Two Mitochondrial Research Compounds from derekpruski@substack.com on 2026-04-24T17:18:04.000Z in mitochondrial DNA. Mitochondria produce it themselves. It belongs to a small class called mitochondrial-derived peptides (MDPs). What the research shows: Activates AMPK, the master energy sensor in cells. When AMPK is active, cells shift into “burn fuel, don’t store it” mode. Improves insulin sensitivity in preclinical models, meaning muscle cell
Fwd: Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine
Score 0.639
· Account oc.tjphuhs@gmail.com
· 4/24/2026, 9:42:34 AM
Fwd: Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine from tjphuhs@gmail.com on 2026-04-24T13:42:34.000Z PPAR part is only released inside cells that express GLP-1 or GIP receptors, so it’s targeted rather than systemic. > Mouse models showed it outperformed GLP-1/GIP co-agonism alone on both weight and glucose control. > This is academic preclinical work — not owned by Lilly, not in human trials — but it demonstrates that pushing past three receptor targets is a legitimate